The effect of Tocilizumab on synovitis of rheumatoid arthritis. Analysis by musculoskeletal ultrasonography

The effect of Tocilizumab on synovitis of rheumatoid arthritis. Analysis by musculoskeletal ultrasonography - The effect of Tocilizumab on synovitis of rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014670

Enrollment

Registered

2014-07-28

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients 1) are fulfilled ACR/EULAR criteria for the classification of RA. 2)have inadequate response to at least one anti rheumatic drug 3) are diagnosed to have indication for Tocilizumab treatment. All patient should give written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion patients 1) have serious infectious disease. 2) have active tuberculosis 3) have past history of hypersensitivity to Tocilizumab 4) are judged as inadequate to tocilizumab treatment by attending doctor

Design outcomes

Primary

Measure	Time frame
The ratio of MKUS remission joint at 52 weeks after TCZ treatment	—

Countries

Japan

Contacts

Public ContactGoichi Kageyama

Kobe University Hospital Rheumatology and Clinical Immunology

kageyama@med.kobe-u.ac.jp078-382-5111

Outcome results